Management tracks: Ex-MiMedx execs to lose compensation

MiMedx Group Inc. (NASDAQ:MDXG) said it will treat four resignations announced this summer, including that of former Chairman and CEO Parker Petit, as "for cause" terminations. The regenerative medicine and biologics company said the decision, made by the board and compensation committee, was based on an independent investigation by its audit committee that found "the ex-employees engaged in, among other things, conduct detrimental to the business and reputation of the Company."